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ABSTRACT
Background To evaluate the safety and tolerability 
of ranibizumab 0.5 mg in patients with uni/bilateral 
neovascular age-related macular degeneration (nAMD) 
and best-corrected visual acuity (BCVA)<2/10 and/or 
second eye affected, regardless of BCVA.
Methods In this 12-month, prospective, multicentre, 
open-label, single arm, pragmatic interventional study, 
patients (N=941) aged ≥ 50 years were to receive 
ranibizumab as per approved label, monthly until 
maximum stable visual acuity (VA) was achieved (initially, 
three or more injections may be required). Thereafter, 
patients were to be monitored monthly for VA and 
treatment was to be resumed if VA was reduced due to 
disease activity.
Results Of the 936 patients treated with ranibizumab 
at least once during the study, 823/113 were 
unilaterally/bilaterally (not simultaneously) treated . The 
mean (SD) number of ranibizumab injections during 
the study was 5.4 (2.9)/10.6 (5.0) injections in uni/
bilaterally treated patients. Three systemic drug-related 
adverse events (AEs) (all serious, all in unilaterally 
treated patients) and 18 systemic AE of special interest 
(AESIs) (11 serious, 16/2 in unilaterally/bilaterally treated 
patients) occurred during the study. The annual incidence 
rate (AIR) (events/1000 person-years) for systemic drug-
related AEs, considering a 15-day/30-day risk period, 
11.0/8.5 for unilaterally treated patients. Considering 
the same risk period, the AIR (events/1000 person-years) 
for systemic AESIs for unilaterally treated patients was 
22.1/19.9. Considering a 30-day risk period, the AIR 
(events/1000 treated eye-years) of ocular drug-related 
AEs was 23 and AESIs was 11.5.
Conclusions The low incidence of AEs and AESIs 
demonstrated the good safety and tolerability of 
ranibizumab in unilaterally/bilaterally treated patients 
with nAMD in this real-world setting.
INTRODUCTION
Age-related macular degeneration (AMD) affects 
nearly 8.7% of the worldwide population, and the 
numbers are projected to increase to around 196 
million in 2020.1–6 In Europe, projections based 
on a recent meta-analysis of AMD prevalence data 
using the European Eye Epidemiology (E3) consor-
tium show an almost doubling of patients with 
AMD by 2040, to between 14.9 and 21.5 million 
with early AMD, and between 3.9 and 4.8 million 
with late AMD.7 In Italy, the PAMDI study showed 
that AMD affects a high percentage of the elderly 
population; of the 1162 patients aged ≥61 years 
included in the study, 62.7% had AMD.8
AMD is one of the most common causes of 
permanent central vision loss in the older popu-
lation aged ≥65 years, predominantly in devel-
oped countries.4 9–12 Neovascular AMD (nAMD) 
accounts for majority of the AMD-associated vision 
loss, even though it accounts for only 10%–20% of 
the overall cases of AMD.12 13
Antivascular endothelial growth factor (VEGF) 
agents are the current standard of care for the 
treatment of visual impairment due to choroidal 
neovascularisation (CNV) secondary to nAMD.12 
Ranibizumab 0.5 mg (Lucentis®; Novartis Pharma 
AG, Basel, Switzerland, and Genentech, South San 
Francisco, California, USA) was the first anti-VEGF 
agent to be approved for this indication, in many 
countries, based on the results from two pivotal 
trials: Antibody for the Treatment of Predomi-
nantly Classic Choroidal Neovascularization in 
Age-Related Macular Degeneration (ANCHOR)14 
and Minimally Classic/Occult Trial of the Anti-
VEGF Antibody Ranibizumab in the Treatment of 
Neovascular Age-Related Macular Degeneration 
(MARINA)15 studies. The burden of the second 
eye developing nAMD is so high that nearly 50% 
of all eyes at risk would require bilateral treatment 
by 3 years.16 However, there are limited data on 
treatment outcomes in the second-affected eyes, 
considering most clinical trials include one study 
eye per patient, to minimise bias and for statistical 
reasons.17
In Italy, after the authorisation of ranibizumab 
for nAMD in 2007,18 limitations were applied on 
reimbursement. Patients with visual acuity (VA) 
<2/10 were excluded and for those patients with 
bilateral disease, the treatment of one eye only was 
reimbursed;19 the physician decided which eye 
to treat, usually the eye with better vision. These 
patients were therefore excluded from the Lucentis 
monitoring registry at the Italian Medicines Agency 
(AIFA) that tracks patients’ eligibility and evaluates 
the appropriateness of treatment in the approved 
indications, as well as collecting safety information 
useful to AIFA to integrate the risk-benefit profile of 
the drug with data from clinical practice. However, 
following the approval of ranibizumab 0.5 mg in 
new indications in 2012, the limitations on the 
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Figure 1 Patient disposition. *Patients who were treated with ranibizumab 0.5 mg at least once and five patients did not received ranibizumab 
treatment. †Percentages are based on the number of patients enrolled (n=941). VA, visual acuity.
reimbursement for patients with VA <2/10 and those with bilat-
eral disease were lifted; hence, the AIFA wanted to assess the 
safety of ranibizumab 0.5 mg in these specific subgroups.
The TWEYEs study (group members of this study are listed 
in online supplementary appendix 1) was specifically conducted 
to address this gap, and evaluated the safety and tolerability of 
ranibizumab 0.5 mg in patients with a VA of <2/10 and those 
with bilateral nAMD, in a real-life setting in Italy.
MATERIALS AND METHODS
Study design
TWEYEs was a 12-month, prospective, multicentre, open-
label, single-arm, pragmatic interventional clinical study that 
was conducted across 107 centres in Italy, from March 2014 
to June 2016.
The study protocol was reviewed and approved by the Ethics 
Committee (EC) of each site and the study was conducted in 
accordance with the Declaration of Helsinki and applicable 
local regulatory requirements. Patients provided written 
informed consent at screening. The study is registered with 
Clinicaltrials. gov (identifier, NCT01986907).
Patients
Patients aged ≥50 years were included if they fulfilled the 
following criteria: eyes with best-corrected VA (BCVA) <2/10 
due to nAMD (20/100 Snellen equivalent), in both unilater-
ally and bilaterally affected patients; fellow eye regardless of 
BCVA in patients with bilateral nAMD, if the first eye had 
been treated with ranibizumab at least 14 days before (fellow 
eyes developing nAMD [newly diagnosed] while the study was 
running were also included in this category).
Key exclusion criteria were active intraocular inflamma-
tion (grade trace or above) in either eye; current or suspected 
ocular or periocular active infection (eg, conjunctivitis, kera-
titis, scleritis, uveitis, endophthalmitis) in either eye; evidence 
of retinal pigment epithelial tear at enrolment or vitrectomy in 
the study eye; ocular disorders that could have confounded the 
interpretation of results, compromised VA or required medical 
or surgical intervention during the study period such as mature 
cataract, retinal vascular occlusion, pre-retinal membrane 
(macular pucker), retinal detachment or macular hole; uncon-
trolled glaucoma (intraocular pressure [IOP]≥30 mm Hg on 
medication or according to investigator’s judgement) in either 
eye; systemic treatment with any VEGF inhibitor, including 
bevacizumab and ziv-aflibercept in the 90 days prior to study 
enrolment; intraocular treatment with any anti-VEGF or 
verteporfin photodynamic therapy within 1 month prior to 
study enrolment; intraocular surgery within 28 days prior to 
study enrolment; stroke (brain ischaemia), transient ischaemic 
attack (TIA) or myocardial ischaemia in the 3 months prior 
to study enrolment; known hypersensitivity to ranibizumab or 
any other component in the formulation. Pregnant or nursing 
women and women of childbearing potential not using effec-
tive methods of contraception were also excluded.
Study treatment
All patients were to be treated as per the approved ranibizumab 
label that was in effect at the time of the study (Summary of 
Product Characteristics [SmPC] 2013)20: Treatment was initi-
ated with one injection per month until maximum VA was 
achieved and/or there were no signs of disease activity that 
is, no change in VA and in other signs and symptoms of the 
disease under continued treatment. In patients with nAMD, 
initially, three or more consecutive, monthly injections may 
be needed. Thereafter, patients were to be monitored monthly 
for VA and treatment was to be resumed in case of VA loss 
due to disease activity. If the patient was already under treat-
ment with ranibizumab at study initiation, treatment during 
the study was to be given as per approved label (monthly until 
maximum VA was achieved).
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Table 1 Baseline patient demographics, ocular and disease 
characteristics (Safety set*)
Total
(N=936)
Unilaterally 
treated
(n=823)
Bilaterally 
treated
(n=113)
Mean (SD) age, years 78.7 (7.3) 78.8 (7.4) 78.1 (6.7)
Age category, n (%)
  <65 years 33 (3.5) 32 (3.9) 1 (0.9)
  65–74 years 212 (22.7) 178 (21.6) 34 (30.1)
  75–84 years 483 (51.6) 427 (51.9) 56 (49.6)
  ≥85 years 208 (22.2) 186 (22.6) 22 (19.5)
Gender, Female, n (%) 582 (62.2) 509 (61.9) 73 (64.6)
Race, n (%)
  Caucasian 935 (99.9) 822 (99.9) 113 (100.0)
  Black 1 (0.1) 1 (0.1) 0
  nAMD affected, n (%)
  Unilaterally 534 (57.1) 534 (64.88) 0
  Bilaterally 399 (42.6) 286 (34.8) 113 (100.0)
  Not affected 3 (0.3) 3 (0.4) 0
Age at first diagnosis, years*
  Mean (SD) 76.6 (7.8) 76.6 (7.9) 76.4 (7.2)
Age at first diagnosis of the treated 
eye, years*
  Mean (SD) 77.1 (7.7) 77.2 (7.7) 76.5 (7.2)
Time from first diagnosis to informed 
consent, years†
  Mean (SD) 2.1 (3.0) 2.2 (3.1) 1.7 (1.9)
Time from first diagnosis of the 
treated eye to informed consent, 
years†
  Mean (SD) 1.6 (2.3) 1.6 (2.3) 1.7 (1.9)
*Data not available for three patients in the unilaterally treated group.
†Consisted of all enrolled patients who signed the informed consent, received at 
least one dose of study drug and had at least one postbaseline safety assessment.
nAMD, neovascular age-related macular degeneration; VA, visual acuity.
Table 2 Systemic drug-related adverse events (by Preferred Term) 
and systemic adverse events of special interest (by Safety Risk and 
Preferred Term; Safety set*)
Preferred term, n (%)
Total
(N=936)
Unilaterally 
treated
(n=879)
Bilaterally 
treated
(n=113)
Patients with at least one drug-
related AE
3 (0.3) 3 (0.3) 0
  Angina pectoris 1 (0.1) 1 (0.1) 0
  Cerebral haemorrhage 1 (0.1) 1 (0.1) 0
  TIA 1 (0.1) 1 (0.1) 0
Patients with at least one systemic 
AESI
18 (1.9) 16 (1.8) 2 (1.8)
  Hypertension 5 (0.5) 4 (0.5) 1 (0.9)
  Blood pressure fluctuation 1 (0.1) 0 1 (0.9)
  Blood pressure increased 2 (0.2) 2 (0.2) 0
  Hypertension 2 (0.2) 2 (0.2) 0
Myocardial infarction 1 (0.1) 1 (0.1) 0
Non-myocardial arterial 
thromboembolic events
5 (0.5) 5 (0.6) 0
  Cerebral haemorrhage 1 (0.1) 1 (0.1) 0
  Cerebrovascular accident 1 (0.1) 1 (0.1) 0
  TIA 3 (0.3) 3 (0.3) 0
Non-ocular haemorrhage 6 (0.6) 5 (0.6) 1 (0.9)
  Cerebral haemorrhage 1 (0.1) 1 (0.1) 0
  Epistaxis 1 (0.1) 1 (0.1) 0
  Haematuria 1 (0.1) 1 (0.1) 0
  Haematuria traumatic 1 (0.1) 1 (0.1) 0
  Intestinal haemorrhage 1 (0.1) 1 (0.1) 0
  Varicose vein ruptured 1 (0.1) 0 1 (0.9)
Venous thromboembolic events 2 (0.2) 2 (0.2) 0
  Pulmonary embolism 2 (0.2) 2 (0.2) 0
The preferred term, 'Cerebral haemorrhage' was classified in both Safety Risks 
'Non-ocular haemorrhage' and 'Non-myocardial arterial thromboembolic events’. 
Each patient could experience more than one adverse event of special interest. 
Patients were counted only once in each row. Terms were coded using MedDRA 
dictionary, version 18.1.
*Consisted of all enrolled patients who signed the informed consent, received at 
least one dose of study drug and had at least one postbaseline safety assessment.
AE, adverse event; AESI, adverse event of special interest; MedDRA, Medical 
Dictionary for Drug Regulatory Activities; SOC, system organ class; TIA, transient 
ischaemic attack.
A patient was considered to be unilaterally treated for the 
whole period if he/she had only one eye treated. When the 
second eye was also treated, the patient was considered to be 
bilaterally treated; however, there was an interval of 14 days 
between treatment of the two eyes.
Objectives
The primary objective was to evaluate the annual incidence 
rates (AIR) of ocular and systemic drug-related adverse events 
(AEs) and AEs of special interest (AESI). The AESIs were those 
events possibly related to ranibizumab as per the Periodic 
Safety Update Report (PSUR) No. 13 and Risk Management 
Plan (RMP) for ranibizumab (online supplementary appendix 
2).
The key secondary objectives included estimating the 
proportion of systemic and ocular AEs stratifying by type of 
patient (ie, treated unilaterally or bilaterally) and describing 
the overall treatment exposure to ranibizumab.
Assessments
Safety assessments included collecting information on any AEs 
throughout the study.
BCVA was to be assessed at baseline and every month, before 
any other procedure or drug administration, using Snellen VA 
testing charts.
Statistical analysis
It was estimated, based on literature data, that in the worst 
case the observed incidence rates of eye with ocular-suspected 
treatment-related AEs in this study should be around 1%, as 
well as the incidence rate of patients with systemic suspected 
treatment-related AEs.14 21 22 Considering a 30% dropout of 
patients/eyes and assuming an average of 50% of the obser-
vation period (ie, 6 months), with a cohort of 5000 eyes, a 
total of 4250 eyes/year yielded a two-sided 95% CI of 0.7% to 
1.3% for an incidence rate of 1%.
The conservative risk periods related to the ranibizumab 
injections were defined as 30 days for ocular AEs and both 15 
and 30 days for systemic events, based on the vitreous elimina-
tion half-life of ranibizumab of about 9 days, intrinsic systemic 
elimination half-life of approximately 2 hours and the systemic 
to vitreous exposure ratio of 1:90,000.23 This in turn would 
have led to reduction of any bias in the study. Based on these 
premises, conservative risk periods related to the ranibizumab 
injections were defined as 30 days for ocular AEs and both 15 
and 30 days for systemic events. Events occurring outside of 
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Figure 2 Annual incidence rates of systemic drug-related AEs and AESIs—15-day and 30-day risk periods* (Safety set†). *Time at risk was defined 
as the sum of the 15 days following each ranibizumab injection. If a patient had more than one injection, his/her risk period was defined as: (1) Time 
elapsed from the injection to the 15 subsequent days—for injections given more than 22 days from the previous; (2) Time elapsed from the first 
injection to the 15 days following the last injection—for injections given up to 22 days from the previous one. The same analysis was performed 
considering a time window of 30 days. †Consisted of all enrolled patients who signed the informed consent, received at least one dose of study drug 
and had at least one postbaseline safety assessment. Lower limits less than 0 were set to 0. In the bilaterally treated patients, no systemic drug-
related AEs occurred during the study, and no systemic AESIs occurred during the 15-day and 30-day risk periods, so it was not possible to calculate 
AIR for this subpopulation. AE, adverse event; AESI, AE of special interest.
these risk periods were considered as occurring in the ‘control 
period’.
The systemic AIR of drug-related AEs, systemic AIR of AESI/
drug-related AEs, ocular AIR of drug-related AEs, and ocular 
AIR of AESI/drug-related AEs are explained in detail in online 
supplementary appendix 3.
The time at risk for systemic events was defined for a 15-day 
and 30-day period, and the time-at-risk for ocular events was 
defined for a 30-day period; these have been explained in 
detail in online supplementary appendix 3.
The safety population consisted of all enrolled patients who 
signed the informed consent, received at least one dose of 
study drug and had at least one postbaseline safety assessment. 
All the AEs occurring from the first injection were considered 
for the analysis in the safety set independently from the loss 
of follow-up.
Two subpopulations, systemic safety and ocular safety 
subpopulations, were introduced in order to evaluate patient 
safety by means of a sensitivity analysis of the primary objec-
tive; details of which are included in online supplementary 
appendix 3 and online supplementary table 1.
Patients/eyes were included in each analysis based on avail-
able assessments and missing data were not replaced. All statis-
tical analyses were produced using SAS for Windows release 
9.4 (64-bit) or later (SAS Institute, Cary, North Carolina, 
USA).
RESULTS
Patient disposition and baseline characteristics
Of the 944 screened patients, 941 (99.7%) were enrolled and 
774 (82.3%) patients completed the study. The main reasons for 
discontinuation were withdrawal of consent (8.3%) followed by 
loss to follow-up (4.0%; figure 1). Among the patients that with-
drew the consent, there were three patients with serious AE.
Of the 941 enrolled patients, 936 (99.5%) patients were 
treated with ranibizumab at least once and the remaining five 
patients did not receive any treatment. All 936 patients were 
included in the safety set. The ocular safety and systemic safety 
subpopulations consisted of 908 (97%) and 886 (94.7%) 
patients, respectively.
At baseline, of the 936 patients included in the safety set, 534 
(57.0%) patients had unilateral nAMD, 399 (42.6%) patients 
had bilateral nAMD and 3 (0.3%) patients were unaffected by 
nAMD (but had CNV secondary to pathological myopia). During 
the study, 823 patients (87.9%, all 534 with unilateral nAMD 
at baseline, 286 with bilateral nAMD and the 3 patients with 
CNV) were treated unilaterally, 57 (6.1%) were treated bilater-
ally (both eyes enrolled at the same time), and the remaining 56 
(6.0%) were first treated unilaterally and subsequently bilater-
ally (when the other eye developed the disease).
In the total population, the mean age (SD) of patients was 
78.7 (7.3) years; 51.6% of the patients were in the age range 
of 75–84 years. The majority of the enrolled patients were 
female (62.2%) and Caucasian (99.9%; table 1). A VA <2/10 
was observed in the treated eye in 89.3% of the 823 unilaterally 
treated (but not necessarily unilaterally affected) patients; and in 
both treated eyes in 27.4% of the 113 bilaterally treated patients 
(online supplementary table 2). Seven hundred and seventy-one 
of the 1049 treated eyes (73.5%) were naïve to ranibizumab at 
baseline; of these, 600 were unilaterally treated and 171 were 
bilaterally treated during the study.
At least one prior or concomitant medical condition was 
reported in 902 (96.4%) patients; 792 (96.2%) patients in the 
unilaterally treated group and 110 (97.4%) patients in the bilat-
erally treated group (online supplementary table 3). The prior 
medical condition with the highest incidence was cataract oper-
ation (n=235, 25.1%), and the active medical condition with 
the highest incidence was hypertension (n=579, 61.9%; online 
supplementary table 3).
There were few patients who entered the study without satis-
fying inclusion criteria while many were included who met the 
exclusion criteria but did not meet the protocol procedure, and 
UniversitÃƒÂƒÃ‚ÂƒÃƒÂ‚Ã‚ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â  degli Studi di M
ilano. Protected by copyright.
 on October 22, 2019 at
http://bjo.bm
j.com
/
Br J Ophthalm
ol: first published as 10.1136/bjophthalm
ol-2019-313907 on 11 M
ay 2019. Downloaded from
 
5Bandello F, et al. Br J Ophthalmol 2019;0:1–10. doi:10.1136/bjophthalmol-2019-313907
Clinical science
Table 3 Annual incidence rates of serious and non-serious systemic drug-related AEs and AEs of special interest (Safety set*)
Incidence rate
15-day risk period 30-day risk period
Number of events
Patient-time- 
at risk, years
Value
(95% CI) Number of events
Patient-time- 
at risk, years
Value
(95% CI)
Drug-related AEs
Serious     
  Overall 2 224.1424 0.0089 (0 to 0.0213) 3 415.1732 0.0071 (0 to 0.0154)
  Unilaterally 2 181.0212 0.0110 (0 to 0.0264) 3 352.5695 0.0085 (0 to 0.0181)
  Bilaterally 0 43.1211 0 (0 to 0) 0 62.6037 0 (0 to 0)
Non-serious None
AEs of special interest
Serious     
  Overall 3 224.1424 0.0134 (0 to 0.0285) 5 415.1732 0.0120 (0.0015 to 0.0226)
  Unilaterally 3 181.0212 0.0166 (0 to 0.0353) 5 352.5695 0.0142 (0.0018 to 0.0266)
  Bilaterally 0 43.1211 0 (0 to 0) 0 62.6037 0 (0 to 0)
Non-serious     
  Overall 1 224.1424 0.0045 (0 to 0.0132) 2 415.1732 0.0048 (0 to 0.0115)
  Unilaterally 1 181.0212 0.0055 (0 to 0.0164) 2 352.5695 0.0057 (0 to 0.0135)
  Bilaterally 0 43.1211 0 (0 to 0) 0 62.6037 0 (0 to 0)
*Consisted of all enrolled patients who signed the informed consent, received at least one dose of study drug and had at least one postbaseline safety assessment. Lower limits 
less than 0 were set to 0.
AE, adverse event.
label schedule (online supplementary table 4). During the study, 
over half of the patients (51.9%) were not monitored monthly 
for VA, and 5 (0.5%) did not receive at least one dose of study 
drug.
Treatment exposure
The mean (SD) number of injections per patient in the overall 
safety population was 6.0 (3.6) and was 5.4 (2.9) in the unilat-
erally treated patients and 10.6 (5.0) in the bilaterally treated 
patients. Over the 1-year period, 30.7% of patients received 
fewer than or equal to three ranibizumab injections, and there 
was a sharp and continuous decrease in the proportion of patients 
receiving subsequent injections—4 injections: 11%, 5 injections: 
11.5%, 6 injections: 12.6%, 7 injections: 7.9% (online supple-
mentary figure 1). No differences were observed in the mean 
(SD) number of injections per treated eye in the two groups; 
5.4 (2.9) in the unilateral treatment group and 5.3 (2.74) in the 
bilateral treatment group (overall safety set: 5.3 [2.9]).
In the treated eyes naïve to ranibizumab at baseline, the mean 
(SD) number of injections was 4.9 (2.5); 4.9 (2.5) and 5.0 (2.6) 
in the unilaterally and bilaterally treated patients, respectively.
Annual incidence rate of systemic drug-related AEs and systemic AEs 
of special interest
A systemic AE was classified under the unilateral or bilateral 
group according to the current treatment of the patient. Hence, 
events that occurred in the 56 bilaterally treated patients who 
were initially treated unilaterally were classified under the unilat-
eral group if they occurred prior to the start of bilateral treat-
ment and under the bilateral group if they occurred after the 
start of bilateral treatment. For this reason, the sum of unilateral 
and bilateral patients shown for the primary outcome is greater 
than the total number of patients.
There were three systemic drug-related AEs reported during 
the study, all serious, and all occurred in unilaterally treated 
patients (table 2). The events of angina pectoris and cerebral 
haemorrhage resulted in study discontinuation. The patient with 
TIA was lost to follow-up. Two of the three events (TIA and 
cerebral haemorrhage), occurred within the 15 day risk period 
and all three occurred within the 30-day risk period.
The AIR considering a 15-day risk period was 0.0089 (8.9 
cases per 1000 person-years; 95% CI 0.0 to 0.0213)) for the 
overall population and 0.0110 (approximately 11 cases per 
1000 person-years; 95% CI 0.0 to 0.0264) for the unilater-
ally treated. With a 30-day risk period, the AIR was 7.2 cases 
per 1000 person-years (95% CI 0.0 to 0.0154) overall and 8.5 
cases per 1000 person-years (95% CI 0.0 to 0.0181) for the 
unilaterally treated (figure 2). No systemic drug-related AEs 
occurred in the bilaterally treated patients, so it was not possible 
to calculate AIR for this subpopulation. In the self-controlled 
case series, with a 15-day and a 30-day risk period, the AIR was 
1.5 cases per 1000 person-years (95% CI 0 to 0.0046) and 0 
cases (95% CI 0 to 0), respectively (figure 2). The number of 
events and AIR for the systemic safety subpopulation in sensi-
tivity analyses were comparable with that of the safety popu-
lation. Systemic AESIs were reported in 18 (1.9%) patients: 
16 in unilaterally treated and 2 in bilaterally treated (table 2). 
Hypertension (n=5), non-myocardial arterial thromboembolic 
events (n=5) and non-ocular haemorrhage (n=6) were the main 
risk categories. Eleven of these events were serious. Seven events 
(traumatic haematuria, blood pressure increase, blood pressure 
fluctuation, hypertension, epistaxis, varicose vein rupture) were 
non-serious (table 2). The five patients who had non-myocardial 
arterial thromboembolic events (cerebral haemorrhage [n=1], 
cerebrovascular haemorrhage [n=1], and TIA [n=3]) received 
1–5 injections prior to the event and were between 77 and 89 
years of age; all had concurrent hypertension and cardiopathy. 
Of the five patients, four were naïve to ranibizumab treatment 
at baseline. Two of these events (cerebral haemorrhage and TIA) 
were suspected by the investigator to be related to treatment.
Four events (haematuria, TIA, epistaxis, and cerebral haem-
orrhage [all except epistaxis were serious]), all in unilaterally 
treated, occurred within the 15-day risk period, corresponding 
to an AIR of approximately 18 events per 1000 person-years 
(95% CI 0.0004 to 0.0353; figure 2). Seven events (five serious 
[haematuria, TIA, epistaxis, cerebral haemorrhage, increased 
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Table 4 Ocular drug-related AEs (by Preferred Term) and ocular AEs 
of special interest during the study (by Safety Risk and Preferred Term; 
Treated eyes of safety set patients*)
Preferred term, n (%)
Total
(N=1049)
Eyes with at least one ocular drug-related AE 9 (0.9)
  Conjunctival haemorrhage 3 (0.3)
  Foreign body sensation in eyes 1 (0.1)
  Ocular discomfort 1 (0.1)
  Ocular hypertension 3 (0.3)
  Retinal degeneration 1 (0.1)
  Retinal haemorrhage† 1 (0.1)
Eyes with at least one ocular AEs of special interest 11 (1.1)
  Intraocular inflammation 4 (0.4)
  Macular oedema 1 (0.1)
  Ocular hyperaemia 1 (0.1)
  Retinal oedema 2 (0.2)
  Intraocular pressure 6 (0.6)
  Ocular hypertension 6 (0.6)
  Retinal detachment and retinal tear 1 (0.1)
  Retinal tear‡ 1 (0.1)
The table summarises ocular AEs that occurred during the study and reported 
independently from the definition of the risk period. Total number of eyes refers 
to both eyes of the safety set patients, since AEs were recorded and counted even 
if occurred on the eye not treated with the study drug. AEs with Site='Both eyes' 
were counted twice in the present analysis (ie, once for each eye). Each eye could 
experience more than one AE. Eyes were counted only once in each row. Terms 
were coded using MedDRA dictionary, version 18.1.
*Consisted of all enrolled patients who signed the informed consent, received at 
least one dose of study drug and had at least one postbaseline safety assessment.
†Identified as serious AE.
‡Search was performed with and without LLT serous detachment of macula.
AE, adverse event;LLT, Lower-level term; MedDRA, Medical Dictionary for Drug 
Regulatory Activities.
Figure 3 Annual incidence rates of ocular drug-related AEs and AESIs—30-day risk period* (Safety set†). *Time at risk was defined as the sum of 
the 30 days following each ranibizumab injection. If a treated eye was given more than one injection, its risk period was defined as: (1) Time elapsed 
from the injection to the 30 subsequent days—for injections given more than 31 days from the previous; (2) Time elapsed from the first injection 
to the 30 days following the last injection—for injections given up to 31 days from the previous. †Consisted of all enrolled patients who signed the 
informed consent, received at least one dose of study drug and had at least one postbaseline safety assessment. The overall annual incidence rate of 
ocular drug-related AEs and AESIs was derived as the total number of ocular drug-related events that occurred during the risk period divided by the 
treated eye-time-at-risk. Treated eye-time-at-risk in years was defined as time elapsed, for any ranibizumab injection, from the injection to a maximum 
of 30+1 subsequent days. Lower limits less than 0 were set to 0. AE, adverse event; AESI, adverse event of special interest.
blood pressure, pulmonary embolism and intestinal haemor-
rhage] and two non-serious [epistaxis and increased blood pres-
sure]), all in unilaterally treated, occurred within the 30-day risk 
period (table 2). The AIR was 16.9 per 1000 person-years (95% 
CI 0.0044 to 0.0294; figure 2). No systemic AESIs occurred in 
the bilaterally treated patients during the 15-day and 30-day 
risk periods, so it was not possible to calculate the AIR for this 
subpopulation. This could be due to low probability of the events 
and the small size of the bilaterally treated patient population. 
In the self-controlled case series, with a 15-day and a 30-day risk 
period, the AIR was 21.6 cases per 1000 person-years (95% CI 
0.0103 to 0.0330) and 24.1 cases per 1000 person-years (95% 
CI 0.099 to 0.0383), respectively (figure 2).
The self-controlled case series analyses considering a 15-day 
risk period and a 30-day risk period provided incidence rate 
ratios of 0.8253 and 0.6996, respectively, indicating a lower rate 
of AESIs in the risk period than in the control period.
The AIR of serious and non-serious systemic drug-related 
AEs and AESIs considering a 15-day and 30-day risk period are 
shown in table 3.
Annual incidence rate of ocular drug-related AEs and ocular AEs of 
special interest
There were nine ocular drug-related AEs reported during the 
study (table 4); one (retinal haemorrhage) was serious. Ocular 
AESI were reported in 11 eyes (1.1%); 6 (0.6%) events were 
related to ocular hypertension, 4 (0.4%) to intraocular inflam-
mation and 1 (0.1%) to retinal tear (table 4); one event of ocular 
hypertension was serious but was considered by the investigator 
to be not related to treatment and the patient was retreated 
again.
Using a 30-day risk period, there were 10 ocular drug-related 
AEs (of which one was serious) and five ocular AESIs (of which 
one was serious). The AIR of ocular drug-related AEs and ocular 
AESI over a 30-day risk period for the overall population and 
self-controlled case series are shown in figure 3. The number 
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Table 5 Annual incidence rates of serious and non-serious ocular 
drug-related AEs and ocular AEs of special interest using a 30 day risk 
period (Treated eyes of safety patients*)
Incidence rate
Number 
of events
Treated eye-time-
at risk, years Value
95% CI
Lower limit Upper limit
Drug-related AEs
  Serious, overall 1 435.1978 0.0023 0 0.0068
  Non-serious, overall 9 435.1978 0.0207 0.0072 0.0342
AEs of special interest
  Serious, overall 1 435.1978 0.0023 0 0.0068
  Non-serious, overall 4 435.1978 0.0092 0.0002 0.0182
Lower limits less than 0 were set to 0.
*Consisted of all enrolled patients who signed the informed consent, received at least one dose of 
study drug and had at least one postbaseline safety assessment.
AE, adverse event.
Table 6 Ocular adverse events (Safety set*)
Preferred term, n (%)
Total
(N=1872)
Eyes with at least one ocular AE† 127 (6.8)
  nAMD 35 (1.9)
  Conjunctivitis 14 (0.8)
  Cataract 13 (0.7)
  Conjunctival haemorrhage 13 (0.7)
  Ocular hypertension 9 (0.5)
Eyes with at least one serious ocular AE 3 (0.2)
  Ocular hypertension 1 (0.1)
  Retinal haemorrhage 1 (0.1)
  Vitreous haemorrhage 1 (0.1)
Eyes with at least one non-serious ocular AE† 125 (6.7)
  nAMD 35 (1.9)
  Cataract 13 (0.7)
  Conjunctival haemorrhage 13 (0.7)
  Ocular hypertension 9 (0.5)
  Conjunctivitis 14 (0.8)
All systemic AEs during the study and reported, independently from the definition of 
the risk period. Each patient could have more than one AE. Except for the number 
of AEs, patients were counted only once in each row. Terms were coded using 
MedDRA dictionary, version 18.1.
*Preferred Terms≥0.5% are included in this table.
†Consisted of all enrolled patients who signed the informed consent, received at 
least one dose of study drug and had at least one postbaseline safety assessment.
AE, adverse event; MedDRA, Medical Dictionary for Drug Regulatory Activities.
of events and AIR of drug-related AEs and AESI for the ocular 
safety subpopulation in sensitivity analyses were comparable 
with that of the safety population.
The incidence rate ratio, risk versus control, was 0.8848, indi-
cating a rate of events during the risk period practically equal to 
that of the control period.
The AIR of serious and non-serious ocular drug-related AEs 
and AESIs were low (table 5).
Proportion of ocular and systemic adverse events
Of the 1872 eyes of the safety set patients (both eyes of each 
patient-treated and not treated), 127 eyes (6.8%) had at least 
one ocular AE after the first drug injection for a total of 167 
ocular events (table 6). The most commonly reported ocular 
AEs were conjunctivitis (0.8%), cataract (0.7%), conjunctival 
haemorrhage (0.7%), blepharitis (0.4%) and retinal epithe-
lium detachment (0.3%; table 6). Ocular serious adverse events 
(SAEs) were reported in three eyes (table 6).
A total of 255 systemic drug-related AEs in 157 patients in 
the safety set were reported during the study, 209 AEs in 132 
unilaterally treated patients and 46 AEs in 25 bilaterally treated 
patients. Systemic SAEs were reported in 60 (6.4%) patients, 
51 (5.8%) unilaterally treated and 9 (8.0%) bilaterally treated 
(table 7).
Ocular AEs in two eyes resulted in treatment discontin-
uation (retinal pigment epithelium detachment and retinal 
degeneration) which was considered by the investigator to be 
treatment-related. Systemic AEs in 15 patients resulted in treat-
ment discontinuation. There were nine deaths reported during 
the study (pulmonary cancer, sepsis, heart attack, septicaemia, 
pulmonary embolism, myocardial ischaemia, cardiac failure [all 
n=1 each], lung cancer [n=2]), but none of them were consid-
ered by the investigator to be related to the study drug.
Discussion
The TWEYEs study is the first real-life pragmatic study in Italy 
that assessed the safety and tolerability of ranibizumab 0.5 mg 
in patients with unilateral or bilateral nAMD and with low VA 
of <2/10. Ranibizumab treatment was well-tolerated in patients 
with nAMD. The population included in this trial was of high 
risk considering that they had a high presence of comorbidities 
and more than 50% of the patients were 75–84 years of age.
Anti-VEGF agents have revolutionised the treatment of visual 
impairment in patients with nAMD.24 25 Clinical experience in 
oncology has shown that systemic VEGF inhibition is associated 
with several ‘classes’ of AEs.26 Although the safety of intravit-
real anti-VEGF agents has been studied extensively, a full under-
standing of the risk of ocular and/or systemic AEs possibly related 
to VEGF inhibition after intravitreal administration, especially 
in high-risk population is still lacking owing to paucity of data.25 
Also, in Italy, the AIFA registry did not routinely capture data 
for patients with nAMD who had bilateral treatment or had low 
baseline VA.
Ranibizumab, an anti-VEGF agent specifically designed for 
intravitreal administration, has a short intrinsic systemic elimina-
tion half-life (2 hours),23 and low serum concentrations (below 
the concentration necessary to inhibit the biological activity of 
VEGF by 50%) following intravitreal injection in patients with 
nAMD. Subsequently ranibizumab does not largely affect plasma 
VEGF or free VEGF levels after intravitreal administration.27–29
The TWEYEs study assessed systemic and ocular AESIs (which 
included all AEs possibly related to ranibizumab as per the PSUR 
and RMP effective at the time of the study), in addition to 
AEs with causal relationship established by the investigator, in 
order to provide the most comprehensive and objective ranibi-
zumab-related AE profile. The AIR of systemic AESIs was 17.8 
events per 1000 person-years considering a 15-day risk period 
following each ranibizumab injection and 16.9 events per 1000 
person-years considering a 30-day risk period. Moreover, in 
TWEYEs, treating patients in both eyes did not increase the like-
lihood of systemic events, as systemic AESIs were observed only 
in two bilaterally treated patients, both events occurred outside 
of the risk periods. These findings are in line with those reported 
previously.30 31
Of the known AEs associated with systemic VEGF inhibi-
tion, the risk of arterial thromboembolic events are of particular 
concern. The incidence of stroke/non-myocardial arterial throm-
boembolic events (0.5% [n=5] including cerebral haemorrhage, 
cerebrovascular accident and TIA) reported in this study was 
similar to what was observed in the pooled analysis of four Euro-
pean registries (0.4%).22
Consistent with findings from randomised controlled trials 
(ANCHOR, MARINA and SUSTAIN) and the analysis of four 
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Table 7 Systemic adverse events (Safety set*)
Preferred term, n (%)
Total
(N=936)
Unilaterally 
treated
(n=879)
Bilaterally 
treated
(n=113)
Patients with systemic AEs, n (%) 157 (16.8) 132 (15.0) 25 (22.1)
  Anaemia 4 (0.4) 3 (0.3) 1 (0.9)
  Lymphadenopathy 1 (0.1) 0 1 (0.9)
  Arrhythmia 1 (0.1) 0 1 (0.9)
  Goitre 1 (0.1) 0 1 (0.9)
  Abdominal pain upper 2 (0.2) 1 (0.1) 1 (0.9)
  Gastro-oesophageal reflux 1 (0.1) 0 1 (0.9)
  Inguinal hernia 2 (0.2) 1 (0.1) 1 (0.9)
  Nausea 2 (0.2) 1 (0.1) 1 (0.9)
  Fatigue 1 (0.1) 0 1 (0.9)
  Fever 10 (1.1) 8 (0.9) 2 (1.8)
  Hepatic lesion 1 (0.1) 0 1 (0.9)
  Bronchitis 9 (1.0) 7 (0.8) 2 (1.8)
  Influenza 16 (1.7) 11 (1.3) 5 (4.4)
  Pneumonia 5 (0.5) 3 (0.3) 2 (1.8)
  Femur fracture 7 (0.8) 6 (0.7) 1 (0.9)
  Fall 2 (0.2) 1 (0.1) 1 (0.9)
  Pancreatic injury 1 (0.1) 0 1 (0.9)
  Rib fracture 2 (0.2) 1 (0.1) 1 (0.9)
  Wrist fracture 1 (0.1) 0 1 (0.9)
  Hypoglycaemia 1 (0.1) 0 1 (0.9)
  Arthralgia 4 (0.4) 4 (0.5) 0
  Osteoarthritis 4 (0.4) 4 (0.5) 0
  Breast cancer 1 (0.1) 0 1 (0.9)
  Prostate cancer treatment 1 (0.1) 0 1 (0.9)
  Depression 3 (0.3) 2 (0.2) 1 (0.9)
  Acute kidney injury 1 (0.1) 0 1 (0.9)
  Renal cyst 1 (0.1) 0 1 (0.9)
  Chronic obstructive pulmonary 
disease
2 (0.2) 1 (0.1) 1 (0.9)
  Cough 4 (0.4) 4 (0.5) 0
  Pneumothorax 2 (0.2) 1 (0.1) 1 (0.9)
  Respiratory disorder 1 (0.1) 0 1 (0.9)
  Respiratory distress 1 (0.1) 0 1 (0.9)
  Respiratory failure 2 (0.2) 1 (0.1) 1 (0.9)
  Mastectomy 1 (0.1) 0 1 (0.9)
  Blood pressure fluctuation 1 (0.1) 0 1 (0.9)
  Peripheral vascular disorder 1 (0.1) 0 1 (0.9)
  Varicose vein ruptured 1 (0.1) 0 1 (0.9)
Patients with serious systemic AEs 60 (6.4) 51 (5.8) 9 (8.0)
  Anaemia 2 (0.2) 1 (0.1) 1 (0.9)
  Goitre 1 (0.1) 0 1 (0.9)
  Hepatic lesion 1 (0.1) 0 1 (0.9)
  Pneumonia 5 (0.5) 3 (0.3) 2 (1.8)
  Femur fracture 7 (0.8) 6 (0.7) 1 (0.9)
  Pancreatic injury 1 (0.1) 0 1 (0.9)
  Breast cancer 1 (0.1) 0 1 (0.9)
  Prostate cancer recurrent 1 (0.1) 0 1 (0.9)
  Chronic obstructive pulmonary 
disease
2 (0.2) 1 (0.1) 1 (0.9)
  Respiratory disorder 1 (0.1) 0 1 (0.9)
  Mastectomy 1 (0.1) 0 1 (0.9)
Patients with non-serious systemic 
AEs
111 (11.9) 90 (10.2) 21 (18.6)
  Lymphadenopathy 1 (0.1) 0 1 (0.9)
Continued
Preferred term, n (%)
Total
(N=936)
Unilaterally 
treated
(n=879)
Bilaterally 
treated
(n=113)
  Arrhythmia 1 (0.1) 0 1 (0.9)
  Bradycardia 1 (0.1) 0 1 (0.9)
  Ventricular extrasystoles 1 (0.1) 0 1 (0.9)
  Abdominal pain upper 2 (0.2) 1 (0.1) 1 (0.9)
  Inguinal hernia 2 (0.2) 1 (0.1) 1 (0.9)
  Nausea 2 (0.2) 1 (0.1) 1 (0.9)
  Fatigue 1 (0.1) 0 1 (0.9)
  Fever 10 (1.1) 8 (0.9) 2 (1.8)
  Bronchitis 9 (1.0) 7 (0.8) 2 (1.8)
  Influenza 15 (1.6) 10 (1.1) 5 (4.4)
  Fall 1 (0.1) 0 1 (0.9)
  Rib fracture 2 (0.2) 1 (0.1) 1 (0.9)
  Wrist fracture 1 (0.1) 0 1 (0.9)
  Hypoglycaemia 1 (0.1) 0 1 (0.9)
  Arthralgia 4 (0.4) 4 (0.5) 0
  Depression 3 (0.3) 2 (0.2) 1 (0.9)
  Cough 4 (0.4) 4 (0.5) 0
  Pneumothorax 1 (0.1) 0 1 (0.9)
  Respiratory distress 1 (0.1) 0 1 (0.9)
  Respiratory failure 1 (0.1) 0 1 (0.9)
  Blood pressure fluctuation 1 (0.1) 0 1 (0.9)
  Peripheral vascular disorder 1 (0.1) 0 1 (0.9)
  Varicose vein ruptured 1 (0.1) 0 1 (0.9)
Preferred Term≥0.5% in any group are included in this table.
All systemic AEs during the study and reported, independently from the definition of 
the risk period. Each patient could have more than one AE. Except for the number 
of AEs, patients were counted only once in each row. Terms were coded using 
MedDRA dictionary, version 18.1.
*Consisted of all enrolled patients who signed the informed consent, received at 
least one dose of study drug and had at least one postbaseline safety assessment.
AE, adverse event; MedDRA, Medical Dictionary for Drug Regulatory Activities.
Table 7 Continued
European registries,14 15 22 32 there was a low number of ocular 
events with ranibizumab injections, which might have been 
caused by the intravitreal injections procedure or by the anti-
VEGF effect. The AIR of ocular AESI occurring within a 30-day 
risk period was 11.5 events per 1000 eye-years and consisted of 
IOP increase, intraocular inflammation and one case of retinal 
tear. Overall, the safety findings from this study were compa-
rable to other pivotal clinical trials with no new critical safety 
findings.14 15 22 32 The mean age of patients enrolled in TWEYEs 
was similar to those enrolled in ANCHOR, MARINA and 
SUSTAIN studies (mean age of approximately 76–79 years).14 15 32 
However, comparison across studies should be interpreted with 
caution considering the difference in study design, treatment 
patterns and eligibility criteria.
The mean number of injections per patient of the safety popu-
lation over 1 year in this trial (6.0) is comparable to the mean 
numbers reported in the observational LUMINOUS study (5.0 
injections)22 and that observed in EPICOHORT (4.4 in the first 
year), a 2-year,multicentre, open-label, observational, non-com-
parative study on patients with nAMD from 54 European clin-
ical centres.31 These mean numbers are similar to the mean 
number of injections (5.6) reported in SUSTAIN, a randomised 
trial with PRN dosing.32 In a multicentre, nAMD database study 
conducted in the UK involving 12 951 eyes of 11 135 patients, 
the mean number of injections in the first year for the first 
treated eyes was 5.6.16 Observations made in TWEYES study in 
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real-life setting in Italy showed that in actual clinical practice, the 
treatment pattern does not necessarily follow the recommended 
treatment regimen, in spite of treatment being available free of 
charge. Not all patients received at least three initial injections 
as recommended in the label, and the proportion of patients 
receiving injections decreased steadily starting from month 4. 
Possible reasons for this could be the busy schedules in clinics 
leading to inadequate patient monitoring and treatment, and the 
disease not being considered as an emergency condition like, for 
example, cardiovascular disease. Also, it was observed that many 
patients who did not meet study entry criteria were included 
in this study and more than 50% patients were not monitored 
monthly for VA.
The limitation of the study is that only about one fifth of the 
planned eyes (target 5000 eyes) were enrolled due to a lower 
than expected enrolment rate. As a result, the CI for the AIR 
of ocular drug-related AEs was greater (2.85%) than what was 
planned (0.6%). In addition, there was no systematic gathering 
of data on prior anti-VEGF medications and this could have led 
to bias in some patients treated with other medications previ-
ously. In addition, previous data related to systemic anti-VEGF 
therapy used for cancer treatment were not collected systemati-
cally leading to a possible bias in this subpopulation. The inability 
to collect systemic AEs in a systematic manner should also be 
taken into consideration and this is reflective of the considerable 
differences observed between drug-related AEs, as judged by the 
investigators, and AIRs of AESI.
The strength of the study is that it is one of the first studies 
to enrol a large number of patients for evaluating the safety of 
ranibizumab 0.5 mg in nAMD, especially in those with VA <2/10 
and those with bilateral nAMD treatment. The pragmatic study 
design, method of data collection and statistical analysis were 
such as to ensure both the study’s internal validity and the appli-
cability of the results to other settings, samples and populations.
In conclusion, the TWEYEs study results confirm the good 
safety and tolerability profile of ranibizumab 0.5 mg, in both 
unilaterally and bilaterally treated, mostly elderly patients with 
nAMD over a 1-year period and in a pragmatic real-world setting 
characterised by high number of protocol deviations and not all 
patients were treated as per label. The low incidence of systemic 
events in this pragmatic clinical study of a predominantly elderly 
population appear to be consistent with the known low systemic 
exposure and short half-life of ranibizumab.
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